LLIN Evaluation in Uganda Project (LLINEUP2) – Effect of longlasting insecticidal nets (LLINs) treated with pyrethroid plus pyriproxyfen vs LLINs treated with pyrethroid plus piperonyl butoxide in Uganda: a cluster-randomised trial

Samuel Gonahasa^{1,7}* Jane Frances Namuganga¹, Martha J Nassali¹, Catherine Maiteki¹ Sebuguzi^{1,2}, Isaiah Nabende¹, Adrienne Epstein³, Katherine Snyman^{1,4,5}, Joaniter I Nankabirwa^{1,6}, Jimmy Opigo², Martin J Donnelly^{7,8}, Grant Dorsey³, Moses R Kamya^{1,6}, Sarah G Staedke^{5,7,9}

- ¹ Infectious Diseases Research Collaboration, Uganda
- ² National Malaria Control Division, Ministry of Health, Uganda
- ³ Department of Medicine, University of California San Francisco, USA
- ⁴ Department of Global Health and Development, London School of Hygiene & Tropical Medicine
- ⁵ Department of Clinical Research, London School of Hygiene & Tropical Medicine, UK
- ⁶ Department of Medicine, Makerere University, Kampala, Uganda
- ⁷ Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK
- ⁸ Wellcome Sanger Institute, Hinxton, UK
- ⁹ Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

Corresponding author: Samuel Gonahasa, Infectious Diseases Research Collaboration, PO Box 7475, Kampala, Uganda; Email: samuelgonahasa@gmail.com; Tel: +256 (0) 772 833471

Samuel Gonahasa MBChB MSc

PhD Fellow/Investigator, Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda <u>samuelgonahasa@gmail.com</u>

Jane F Namuganga MD MHS

Project Coordinator Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda <u>jnamuganga@idrc-uganda.org</u>

Martha J Nassali MBChB MPH

Survey Coordinator Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda <u>mnassali@idrc-uganda.org</u>

Catherine Maiteki-Sebuguzi MBChB MSc

Principal Medical Officer Policy and Strategy National Malaria Control Division Uganda Ministry of Health, Kampala, Uganda <u>cmaiteki@gmail.com</u>

Isaiah Nabende BSc

Data Manager Infectious Disease Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda inabende@idrc-uganda.org

Adrienne Epstein PhD

Post-Doctoral Research Associate Department of Medicine University of California, San Francisco San Francisco, CA 94110 USA <u>adrienne.epstein@ucsf.edu</u>

Katherine Snyman MPH

PhD student, LSHTM Research Associate Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda <u>Katherine.snyman@lshtm.ac.uk</u>

Joaniter I Nankabirwa MBChB PhD Lecturer

Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda <u>jnankabirwa@yahoo.co.uk</u>

Jimmy Opigo MBChB MPH

Assistant Commissioner Health Services Manager, National Malaria Control Division Uganda Ministry of Health, Kampala, Uganda opigojimmy@gmail.com

Martin J Donnelly PhD ScD

Professor of Evolutionary Genetics Liverpool School of Tropical Medicine Pembroke Place, Liverpool L3 5QA, UK martin.donnelly@lstmed.ac.uk

Grant Dorsey MD MPH PhD

Professor of Medicine Department of Medicine University of California, San Francisco San Francisco, CA 94110 USA grant.dorsey@ucsf.edu

Moses R Kamya MBChB MMed MPH PhD

Professor of Medicine Department of Medicine, Makerere University College of Health Sciences Infectious Diseases Research Collaboration 2C Nakasero Hill Road, Kampala, Uganda <u>mkamya@infocom.co.ug</u>

Sarah G Staedke MD PhD

Professor of Malaria & Global Health Department of Vector Biology Liverpool School of Tropical Medicine Liverpool UK <u>sarah.staedke@lstmed.ac.uk</u>

1 Abstract

2	Background. We embedded a pragmatic, cluster-randomised trial into Uganda's national campaign
3	to distribute long-lasting insecticidal nets (LLINs) in 2020–2021, comparing LLINs treated with
4	pyrethroids plus the synergist piperonyl butoxide (PBO), to LLINs treated with pyrethroids plus
5	pyriproxyfen, an insect growth regulator.
6	Methods. Target communities surrounding public health facilities (clusters, n=64), covering 32 high-
7	burden districts not receiving indoor residual spraying, were included. Clusters were randomised 1:1
8	in blocks of two by district to receive: (1) pyrethroid-PBO LLINs (PermaNet 3.0, n=32) or (2)
9	pyrethroid-pyriproxyfen LLINs (Royal Guard, n=32). LLINs were delivered from 7 November 2020 to
10	26 March 2021 and malaria outcome data were collected until 31 March 2023. Estimates of malaria
11	incidence in residents of all ages (the primary outcome) were generated for each cluster from
12	enhanced health facility surveillance data. At 12- (24 November 2021 to 1 April 2022) and 24-months
13	(23 November 2022 to 21 March 2023) post-LLIN distribution, cross-sectional community surveys
14	were conducted in randomly selected households (at least 50 per cluster, 3,200 per survey).
15	Findings. In the two years following LLIN distribution, 186,364 episodes of malaria were diagnosed in
16	cluster residents during 398,931 person-years of follow-up. Malaria incidence after 24-months was
17	lower than at baseline in both arms (pyrethroid-PBO: 465 vs 676 episodes per 1000 person-years;
18	pyrethroid-pyriproxyfen: 469 vs 674 episodes per 1000 person-years); but the difference between
19	the arms was not statistically significant (incidence rate ratio 1.06, 95% confidence interval [CI] 0.91–
20	1.22, p=0.47). Two years post-distribution, ownership of at least one LLIN for every two household
21	residents was low in both arms (41.1% pyrethroid-PBO vs 38.6% pyrethroid-pyriproxyfen). Parasite
22	prevalence in children aged 2-10 years was no different between the arms in either survey and
23	similar results were observed for prevalence of anaemia in children aged 2-4 years.
24	Interpretation. The effectiveness of pyrethroid-PBO LLINs and pyrethroid-pyriproxyfen LLINs was no
25	different in Uganda, but two years after mass distribution, LLIN coverage was inadequate.

Funding. US National Institutes for Health, Bill and Melinda Gates Foundation

29

- 30 Trial registration
- 31 NCT04566510. Registered 28 September 2020, <u>https://clinicaltrials.gov/ct2/show/NCT04566510</u>

32

33 Keywords

- 34 malaria, long-lasting insecticidal nets (LLINs), insecticide treated nets (ITNs), piperonyl butoxide,
- 35 PermaNet 3.0, pyriproxyfen, Royal Guard, cluster-randomised trial, Uganda

36

37 Word count = 4,782

38 Introduction

39	Between 2000 and 2015, intensified efforts to control malaria substantially reduced malaria case
40	incidence and parasite prevalence across Africa, with the majority of cases averted attributed to the
41	distribution of long-lasting insecticidal nets (LLINs) [1]. More recently, however, progress on malaria
42	control has stalled. Globally, malaria cases increased from 230 million in 2015 to 247 million in 2021,
43	with 95% of cases reported from Africa [2]. Four African countries, including Uganda, accounted for
44	nearly half of all cases worldwide in 2021. In Uganda, implementation of malaria control
45	interventions including repeated national LLIN distribution campaigns, case management with
46	effective artemisinin-based combination therapy, and indoor residual spraying (IRS) of insecticides in
47	selected high-transmission districts reduced the malaria burden, with parasite prevalence by
48	microscopy in children under-five decreasing from 45% in 2009 to 9% in 2018-2019 [3]. Progress in
49	malaria control in Uganda has been difficult to sustain, however, despite ongoing implementation of
50	effective control interventions [4, 5].
51	
52	In Uganda, and across Africa, LLINs are the most widely-used malaria prevention tool [6]. As
53	recommended by the World Health Organization (WHO), the Ugandan Ministry of Health distributes
54	LLINs through mass campaigns approximately every three years, aiming for universal coverage [7].
55	Currently, LLINs rely on pyrethroid insecticides, but resistance to pyrethroids has spread rapidly in
56	malaria vectors, threatening the effectiveness of LLINs [2, 8]. The causal mechanisms of pyrethroid
57	resistance are complex, but point mutations in the voltage-gated sodium channel where pyrethroids
58	bind ('knock down resistance'), and alterations in enzymes that metabolize pyrethroids, commonly
59	cytochrome P450s, are key features [9, 10].
60	
61	To combat emerging resistance, next generation LLINs that incorporate a second chemical in
62	addition to pyrethroids have been developed. One such net includes piperonyl butoxide (PBO), a

63 synergist which inhibits P450 enzymes, overcoming metabolic resistance mechanisms in mosquitoes,

64	and partially restoring susceptibility to pyrethroids [11, 12]. Supported by evidence from trials
65	conducted in Tanzania and Uganda [13-15], demonstrating the superiority of pyrethroid-PBO LLINs
66	over pyrethroid-only LLINs, the WHO endorsed deployment of pyrethroid-PBO LLINs in areas where
67	malaria vectors exhibit pyrethroid resistance. The WHO's recommendation was conditional due to
68	uncertainty about the cost-effectiveness and durability of pyrethroid-PBO LLINs [16, 17]. Another
69	new type of LLIN combines pyrethroids with pyriproxyfen, an insect growth regulator which acts as a
70	sterilising agent, reducing the vector population density and lifespan of adult mosquitoes.
71	Pyrethroid-pyriproxyfen LLINs are promising, but trials comparing these nets to pyrethroid-only
72	LLINs in Burkina Faso and Tanzania have produced mixed results [18, 19]. Additional studies
73	evaluating the effectiveness of nets incorporating pyriproxyfen are needed.
74	
75	In 2020-2021, two next generation LLINs including pyrethroid-PBO LLINs and pyrethroid-
76	pyriproxyfen LLINs were distributed in Uganda, providing an opportunity to evaluate the
77	effectiveness of these LLINs in a 'real-world' setting. With support from the Ministry of Health,
78	donors, and partners, a large cluster-randomised trial (LLINEUP2) was embedded within this national
79	distribution campaign, allowing us to rigorously compare the impact of these LLINs on
80	epidemiological indicators. We aimed to test the hypothesis that malaria incidence would be lower
81	in intervention clusters (randomised to receive pyrethroid-pyriproxyfen LLINs) than in control
82	clusters (randomised to receive pyrethroid-PBO LLINs). Malaria surveillance data at health facilities
83	were collected between 17 October 2020 and 31 March 2023, and cross-sectional community survey
84	data between 24 November 2021 to 1 April 2022 (12-months) and 23 November 2022 to 21 March
85	2023 (24-months) post-LLIN distribution.
86	

87 Methods

88 Study setting

89	Districts with high malaria burden were selected to participate in the study (figure 1) if they were
90	not receiving IRS and were scheduled to receive pyrethroid-PBO LLINs. A cluster was defined as the
91	target area surrounding public health facilities with enhanced malaria surveillance, known as Malaria
92	Reference Centres (MRCs) [20]. MRCs are high-volume, level III or IV health centres with an
93	estimated outpatient department attendance of 1,000–3,000 patients per month and a functional
94	laboratory. To avoid contamination, MRCs within the same district were selected from different sub-
95	counties. Overall, 64 clusters located in 32 districts were included in the trial.
96	
97	Assignment of interventions
98	Cluster definition
99	The unit of randomisation (cluster) was the 'target area' surrounding each MRC. Target areas had an
100	estimated population of at least 1,200 residents and included the MRC's village plus adjacent villages
101	without another health facility, located within the same sub-county as the MRC village, and with
102	similar malaria incidence as the MRC village. All households within the target areas were mapped
103	and enumerated to determine the population and to generate a sampling frame for community
104	surveys.
105	
106	Cluster randomisation
107	Clusters were randomised in a 1:1 ratio to receive either pyrethroid-PBO LLINs (PermaNet 3.0,
108	Vestergaard Sàrl, Switzerland), or pyrethroid-pyriproxyfen LLINs (Royal Guard, Disease Control
109	Technologies, USA). Randomisation was carried out by a member of the study team based outside of
110	Uganda at the University of California, San Francisco, who had no direct links to the net distribution
111	team at the Ministry of Health in Uganda. To improve comparability between arms, MRCs were
112	selected in each district for allocation to the intervention and control arm in a matched pair-wise
113	fashion. Clusters were randomised in blocks of two, with each block representing a district

114 containing two clusters, using the 'runiform' command in STATA version 14.2 (StataCorp, Texas,

115 USA).

116

117 LLIN distribution

- 118 LLINs were delivered free-of-charge through a mass distribution campaign led by the Ugandan
- 119 Ministry of Health and partners from 7 November 2020 to 26 March 2021. Members of the research
- 120 team engaged with Uganda's national committees that coordinated the campaign, to ensure that
- 121 LLINs were allocated according to the randomisation scheme. For each cluster we used a 'fried egg'
- approach (figure 1); LLINs were delivered to the entire sub-county, including the MRC and several
- 123 other villages beyond the MRC target area ('egg white'), while outcomes were measured in the MRC
- 124 target areas ('egg yolk'). Nets were distributed from house-to-house, targeting all households within

125 the subcounty and aiming for population level coverage of at least 85%.

126

127 Health facility-based surveillance

At each MRC, individual-level data for all patients recorded into standardised outpatient department registers were entered into an Access database by on-site data entry officers. Primary data captured included location of residence (parish and village), age, gender, temperature, history of fever, type

- of malaria test done, malaria test results, diagnoses given, and any treatments prescribed. Data from
- each MRC was submitted to the research team monthly using a secure on-line system. Data
- 133 captured from 1 November 2019 to 31 March 2023 was used to generate estimates of malaria

134 incidence.

135

136 *Cross-sectional surveys*

137 Cross-sectional community surveys were conducted 12-months (24 November 2021 to 1 April 2022)

- and 24-months (23 November 2022 to 21 March 2023) after nets were distributed. A study team,
- 139 consisting of a clinician and research assistant carried out the surveys. Households were randomly

140	selected from the enumeration lists for each cluster and screened until 50 households with at least
141	one child aged 2–10 years was enrolled from each cluster (with a total of 64 clusters, leading to at
142	least 3,200 households per survey). If an enrolled household had no children of appropriate age,
143	they were included in the household survey only, but did not take part in the clinical survey.
144	Households were included if at least one adult aged 18 years or older was present, the adult was
145	usually resident and slept in the household on the night before the survey, and the adult provided
146	informed consent. Households were excluded if the house had been destroyed or could not be
147	found, the house was vacant, or no adult resident was home on more than three occasions.
148	
149	A household questionnaire adapted from prior surveys, including the national Malaria Indicator
150	Survey, was administered to the head of the household (or their designate), after obtaining their
151	consent, using a hand-held tablet computer. Information was gathered on the characteristics of
152	households and residents, proxy indicators of wealth including ownership of assets, and ownership
153	and use of LLINs in the households.
154	
155	All children aged 2–10 years from enrolled households were eligible for the clinical survey if they
156	were usually resident and present in the household on the night before the survey, their parent or
157	guardian provided informed consent, and the child provided assent if they were aged 8 years or
158	older. Children not home on day of survey were excluded. The clinical surveys included
159	measurement of temperature, subjective fever, and a finger-prick blood sample for preparation of
160	thick blood smears, and haemoglobin measurement (in children aged 2–4 years).
161	
162	Participants with a temperature of \geq 38.0°C, or who reported fever in the past 48h, had a rapid
163	diagnostic test (RDT) done (Bioline Malaria Ag P.f/Pan, Abbott Diagnostics, Inc). Participants with a
164	positive RDT were treated with artemether-lumefantrine, or referred if they had evidence of severe

165	disease. Any participants with a haemoglobin <7.0 g/dL or other concerning clinical symptoms were
166	referred for further management.

167

168 *Laboratory procedures*

- 169 Thick blood smears obtained in the cross-sectional surveys were dried and transported to the
- 170 Infectious Diseases Research Collaboration Molecular Research Laboratory in Kampala within seven
- 171 days for processing and reading. Slides were stained with 3% Giemsa for 30 minutes and read by
- 172 experienced laboratory technologists. Parasite densities were calculated by counting the number of
- asexual parasites, per 200 leukocytes (or per 500, if the count was less than 10 parasites per 200
- 174 leukocytes), assuming a leukocyte count of 8,000/µl. A thick blood smear was considered negative
- 175 when the examination of 100 high power fields did not reveal asexual parasites. For quality control,
- all slides were read by a second microscopist and a third reviewer settled discrepant readings,
- defined as (1) positive versus a negative thick blood smear, (2) parasite density differing by $\geq 25\%$.
- 178 Haemoglobin measurements were made using a portable HemoCue analyzer (HemoCue, Ängelholm,

179 Sweden).

180

181 *Outcome measures*

182 The primary outcome of the trial was cumulative incidence of symptomatic malaria cases in cluster 183 residents of all ages captured at the MRCs over the 24 months following LLIN distribution. The total 184 number of malaria cases for each cluster was determined from the number of laboratory-confirmed 185 malaria cases diagnosed at the MRC in patients residing within the target area, over the two-year 186 follow-up period, correcting for cluster residents with suspected malaria seen at the MRC who did 187 not undergo laboratory testing, and for patients with laboratory-confirmed malaria whose village of 188 residence was unknown (due to missing data). The population of the MRC target area determined in 189 the enumeration surveys was used as the denominator for incidence calculations for each cluster 190 with a constant growth factor of 0.29% per month, derived from the UN Department of Economic

191 and Social Affairs Population Division World Population Prospects data

192 (https://population.un.org/wpp/), which estimated an annual growth rate of 3.46% in 2019 (divided

- 193 by 12 for the monthly rate of 0.29%).
- 194
- 195 Secondary outcomes for the cross-sectional community surveys included LLIN ownership (the
- 196 proportion of households that owned at least one LLIN), adequate LLIN coverage (the proportion of
- 197 households that owned at least one LLIN for every two occupants), LLIN use (the proportion of
- 198 household residents who reported sleeping under an LLIN the previous night), prevalence of
- 199 parasitaemia (in children aged 2–10 years), and prevalence of anaemia (in children aged 2–4 years).
- 200

201 Sample size calculations

202 Our sample size of 32 clusters per arm was calculated to detect a 26% difference (incidence rate 203 ratio [IRR] = 0.74) in malaria incidence between the two study arms over the 24 months following 204 LLIN distribution (the primary endpoint of the study), given a power of 80% and a two-sided significance level of 0.05, assuming an incidence of 332 malaria cases per 1,000 person-years in the 205 206 control arm and a coefficient of variation of 0.42, which was calculated from the 14 MRCs where 207 estimates of malaria incidence over 6 months were available at the time of protocol development. 208 209 For the cross-sectional community surveys, we planned to sample all eligible children aged 2–10 210 years from 50 households in the 64 clusters in each survey. Assuming an average of 1.8 children 211 aged 2-10 years per household, we estimated that 5,760 children from 3,200 households would be 212 included. Assuming a coefficient of variation of 0.40, across a wide range of prevalence measures in 213 the control arm (10-70%), our sample size allowed us to detect a 25–28% difference in the 214 prevalence measure of interest, equivalent to a prevalence ratio of 0.72–0.75, given a power of 80%

and a two-sided significance level of 0.05.

216

217 Analytical issues

218	All analyses were conducted using an intention-to-treat approach. We compared cluster-level
219	estimates of the incidence of malaria between the intervention (pyrethroid-pyriproxyfen LLINs) and
220	the control arm (pyrethroid-PBO LLINs) using a mixed effects Poisson regression model with a
221	random effect at the district level (each district included two clusters, randomised to one of the two
222	study arms) and adjustment for log-transformed estimates of the baseline malaria incidence (three
223	months prior to the intervention) for each cluster. The effect of the intervention was expressed as an
224	incidence rate ratio (incidence in the intervention arm/incidence in the control arm).
225	
226	For the cross-sectional surveys, separate analyses were conducted 12- and 24-month following LLIN
227	distribution. Houses were classified as 'modern' (synthetic walls and roofs, eaves closed or absent)
228	or 'traditional' (all other construction). We compared individual level estimates of the prevalence of
229	parasitaemia and anaemia between the intervention (pyrethroid-pyriproxyfen LLINs) and the control
230	arm (pyrethroid-PBO LLINs) using a mixed effects logistic regression model with random effects at
231	the level of the cluster and household. We compared household-level estimates of LLIN ownership,
232	coverage, and use with a mixed effects logistic regression model with a random effect at the level of
233	the cluster. Effects of the intervention were expressed as odds ratios (odds in the intervention
234	arm/odds in the control arm).
235	

236 **Research ethics approval and participant consent**

The research included in this trial was conducted under two study protocols. The Implementation
Project Pilot Study covered enumeration of the target areas and estimation of malaria incidence
using health facility surveillance data. This project was approved by the Makerere University School
of Medicine Research & Ethics Committee (SOMREC, Ref 2019-087), the Ugandan National Council of
Science and Technology (UNCST, Ref HS 2659), and the University of California, San Franciso Human
Research Protection Program Institutional Review Board (UCSF Ref 19-27957).

243

244	The LLINEUP2 trial	protocol provideo	d approval for the full	trial, including the	cross-sectional surveys
244	THE LLINLOFZ UIA	protocor provided	a approvation the run	that, including the	cioss-sectional surve

- and was approved by the Makerere University School of Medicine Research & Ethics Committee
- 246 (SOMREC Ref 2020-193), Ugandan National Council for Science and Technology (UNCST Ref
- 247 HS1097ES), the University of California San Francisco Human Research Protection Program
- 248 Institutional Review Board (UCSF Ref 20-31769), and the London School of Hygiene & Tropical
- 249 Medicine Ethics Committee (LSHTM Ref 22615). Prior to enrolment into the clinical surveys, written
- informed consent was obtained from a parent or guardian for all children aged less than 18 years
- and the child provided assent if they were aged 8 years or older.
- 252

253 **Results**

254 Characteristics of clusters, households, and residents

255 Of the 64 clusters (figure 2), 32 were randomised to receive pyrethroid-PBO LLINs, and 32 to receive

- 256 pyrethroid-pyriproxyfen LLINs. At baseline, the median estimated population of the clusters (MRC
- target areas) was 3,070 (range 1,084–5,915) in the pyrethroid-PBO LLIN arm, and 2,493 (range
- 258 756—8,663) in the pyrethroid-pyriproxyfen LLIN arm.

- 260 Cross-sectional community surveys were carried out in all clusters (table 1) at 12-months (24
- 261 November 2021 to 1 April 2022) and 24-months (23 November 2022 to 21 March 2023) post-LLIN
- distribution. Characteristics of households enrolled in both surveys were similar across study arms
- 263 (12-months: n=3,518, median 53 per cluster, range 50178; 24-months: n=3,372, median 52 per
- cluster, range 50264). In both surveys, over half of households had three or more persons per
- sleeping room (55.8%) and were constructed of traditional materials (57.1%). Overall, 7,781 bed nets
- were surveyed at 12-months, and 6,306 at 24-months (table 1). Most nets (86.1%) were obtained in

the most recent universal coverage campaign (UCC), and nearly all nets (96.1%) were obtained for

268 free.

269

270	In total, 16,189 household residents were	e surveyed at 12	2-months, and	16,706 at 24-mc	onths (table

- 271 1); over half of residents were women (54.5%). In both surveys, the age distribution of residents was
- similar across the study arms. Children aged 2-10 years enrolled in the clinical survey (figure 2) were
- tested for parasitaemia (12-months: n=4,893, median 73 per cluster, range 542122; 24-months:
- n=4,519, median 68 per cluster, range 50294). Children aged 2-4 years were tested for anaemia (12-
- 275 months: n=2,087, median 31 per cluster, range 17248; 24-months: n=1,908, median 30 per cluster,
- 276 range 14248).

277

278 LLIN delivery

LLINs were delivered in the study area by the Ministry of Health and partners from 7th November
 2020 to 26th March 2021. In total, 1,329,273 LLINs were allocated for distribution to the sub-counties
 surrounding each cluster, including 632,359 pyrethroid-pyriproxyfen LLINs and 696,914 pyrethroid-

282 PBO LLINs. A cross-sectional survey was conducted in April-May 2021 in 12 clusters from 12 selected

- districts to evaluate the impact of the LLIN distribution campaign. As previously reported, [21] 1-5
- 284 months after LLIN distribution, household LLIN ownership was high. Of 634 households surveyed,
- 285 609 (96.1%) owned at least one LLIN. However, only 360 (56.8%) households owned at least one
- 286 UCC LLIN for every 2 residents, while 374 (59.0%) were adequately covered by LLINs of any type.
- 287

288 Impact on primary outcome: malaria incidence

In the three months prior to completion of LLIN distribution (baseline), 32,384 episodes of malaria
were diagnosed in residents of the clusters (MRC target areas) over 47,945 per-years of follow-up
(table 2, figure 3). The baseline incidence of malaria in the two study arms was similar (676 episodes)

292	per 1,000 person-years in the pyrethroid-PBO LLIN arm, and 674 episodes per person-year in the
293	pyrethroid-pyriproxyfen LLIN arm). In the first 4 months following LLIN distribution, malaria
294	incidence decreased in both study arms, but began to increase again 5-months post-distribution
295	(figure 3). Overall, in the two years after LLIN distribution, 186,364 episodes of malaria were
296	diagnosed in cluster residents during 398,931 person-years of follow-up (table 2). The incidence of
297	malaria post-LLIN distribution was lower than baseline in both study arms (465 episodes per 1000
298	person-years in the pyrethroid-PBO arm, and 469 episodes per person-year in the pyrethroid-
299	pyriproxyfen arm), but the difference between the two arms was not statistically significant
300	(incidence rate ratio (IRR) 1.06, 95% confidence interval (CI) 0.91−1.22, p🗉=🖾0.47).
301	
302	Impact on secondary outcomes: LLIN ownership, coverage and use
303	Trends in LLIN ownership, coverage and use were similar in both study arms at 12-months and 24-
304	months (table 3). Most households reported owning at least one LLIN at 12-months (91.9%
305	pyrethroid-PBO vs 89.9% pyrethroid-pyriproxyfen), but ownership dropped at 24-months in both
306	study arms (82.5% pyrethroid-PBO vs 80.0% pyrethroid-pyriproxyfen). In contrast, adequate
307	coverage of LLINs (one LLIN for every two residents) was low at 12-months (59.9% pyrethroid-PBO vs
308	56.6% pyrethroid-pyriproxyfen) and fell even further at 24-months (41.1% pyrethroid-PBO vs 38.6%
309	pyrethroid-pyriproxyfen). Similarly, although most household residents reported sleeping under a

- 310 LLIN the previous night (74.2% pyrethroid-PBO vs 76.1% pyrethroid-pyriproxyfen); reported use of
- 311 LLINs dropped at 24-months (63.6% pyrethroid-PBO vs 61.6% pyrethroid-pyriproxyfen).

312

313 Impact on secondary outcomes: parasite prevalence and anaemia prevalence

Parasite prevalence in children aged 2-10 years was no different in the two study arms at 12-months

- and 24-months post-LLIN distribution (table 3). Parasite prevalence at 12-months was 21.6% in the
- 316 pyrethroid-PBO arm vs 26.4% in the pyrethroid-pyriproxyfen arm (odds ratio [OR] 1.49 [95% CI:

317	0.88–2.51], p=0.14). Similar	results were observed at the 24	-month timepoint (26.1% in the
	-/ - /		

- 318 pyrethroid-PBO arm vs 29.5% in the pyrethroid-pyriproxyfen arm (OR 1.29 [95% CI: 0.81–2.05],
- 319 p=0.29). The prevalence of anaemia (haemoglobin < 11 g/dL) in children aged 2-4 years decreased
- 320 substantially between 12-months and 24-months, but there was no difference between the study
- 321 arms at the two timepoints (table 3). Anaemia prevalence at 12-months was 36.2% in the
- 322 pyrethroid-PBO arm vs 34.0% in the pyrethroid-pyriproxyfen arm (OR 0.88 [95% CI: 0.57–1.34],
- p=0.44). At 24-months, prevalence anaemia dropped to 19.7% in the pyrethroid-PBO arm vs 19.0%
- 324 in the pyrethroid-pyriproxyfen arm (OR 0.95 [95% CI: 0.62–1.46], p=0.81).
- 325

326 Costing of LLINs

We originally planned to conduct a cost-effectiveness analysis of the two LLINs studied, but given the lack of difference in LLIN effectiveness, we limited our assessment to a costing exercise. When the study LLINs were purchased (in 2019), the pyrethroid-pyriproxyfen LLINs (Royal Guard, \$2.28 USD per net) were slightly less expensive than the pyrethroid-PBO LLINs (PermaNet 3.0, \$2.51 USD per net). As of April 2023, market prices of the pyrethroid-pyriproxyfen LLINs were \$0.77 USD lower per net than pyrethroid-PBO LLINs (\$2.30 USD for Royal Guard vs \$3.07 USD for PermaNet 3.0) [22].

333

334 Discussion

In this pragmatic, cluster-randomised trial embedded into Uganda's 2020–2021 LLIN distribution campaign, we compared the impact of two next generation LLINs on malaria incidence across 32 districts in Uganda. Despite a marked reduction in malaria incidence following LLIN distribution in both study arms, there was no difference in malaria incidence among residents of all ages, parasite prevalence among children 2-10 years of age, or anaemia prevalence among children 2-4 years of age from clusters that received pyrethroid-pyriproxyfen LLINs compared to those that received pyrethroid-PBO LLINS. Given the lack of difference in effectiveness of the two LLINs studied, we did

not conduct a cost-effectiveness analysis as originally planned. Faced with similar effectiveness, the
choice of LLIN should be guided by price and other factors. Importantly, LLINs will only be effective if
coverage is high, and nets are used. Two years post-distribution, we found only around 40% of
households were adequately covered by LLINs, while just over 60% of residents reported sleeping
under a LLIN the previous night.

347

348 Pyrethroid-PBO LLINs were superior to pyrethroid-only LLINs in two trials conducted in east Africa, 349 including the original LLINEUP trial in Uganda [13-15]. A Cochrane systematic review incorporating 350 both trials concluded that pyrethroid-PBO LLINs reduced parasite prevalence compared to 351 pyrethroid-only LLINs up to 21–25 months post-distribution (OR 0.79 [95% CI 0.67–0.95]), in areas 352 with highly pyrethroid-resistant mosquitoes (defined as < 30% mosquito mortality in discriminating 353 dose assays) [12]. Based on this evidence, the WHO issued a conditional recommendation in 2022 354 supporting the deployment of pyrethroid-PBO LLINs instead of pyrethroid-only LLINs 'in areas with 355 ongoing malaria transmission where the principal malaria vector(s) exhibit pyrethroid resistance' 356 [16]. However, pyrethroid-PBO LLINs have several potential limitations. Widespread pyrethroid 357 resistance has been reported in Uganda [23, 24], and across Africa, with both knock-down and 358 metabolic resistance described across several settings [11]. PBO is a synergist, not an insecticide, and 359 can only restore sensitivity to pyrethroid insecticides if resistance is due to specific metabolic 360 mechanisms. Moreover, PBO may fail to overcome high-level pyrethroid resistance [25]. Questions 361 about the bioefficacy, durability, and lifespan of PBO-pyrethroid LLINs have also been raised [12, 16], 362 given concerns about the rapid degradation of PBO from nets raised by studies conducted in Kenya 363 and Tanzania [26, 27]. In Uganda, an evaluation of nets distributed in the first LLINEUP trial found 364 that while the pyrethroid content of LLINs was relatively stable, the PBO content fell significantly 365 over two years; by 55% in Olyset Plus and 58% in PermaNet 3.0 [17]. The bioefficacy of the 366 pyrethroid-PBO nets also declined over time with only 46% and 79% of mosquitoes knocked down 367 by Olyset Plus and PermaNet 3.0, respectively, after 25 months [17]. The WHO has highlighted the

368	need for further research on the effectiveness of pyrethroid-PBO LLINs, specifically in areas of lower
369	transmission intensity and where pyrethroid resistance is not driven by cytochrome P450
370	metabolism, as well as on the durability and cost-effectiveness of pyrethroid-PBO LLINs [16].
371	
372	Treating LLINs with a combination of insecticides with different modes of action may improve
373	efficacy and help to prevent or delay the spread of insecticide resistance. Pyriproxyfen is an insect
374	growth regulator, which has traditionally been used as a larvicide [28], but also acts as a sterilising
375	agent, reducing the fecundity (egg laying), fertility (production of viable offspring), and longevity of
376	adult mosquitoes [29]. Pyriproxyfen has a different mechanism of action than pyrethroids, is
377	effective at very low concentrations, and is safe in humans [28]. In a step-wedge, cluster-randomised
378	trial conducted in Burkina Faso, pyrethroid-pyriproxyfen LLINs (Olyset Duo) were associated with
379	lower clinical incidence in children aged 6–59 months, and lower entomological inoculation rates
380	than pyrethroid-only LLINs (Olyset Net) [18]. More recently, a cluster-randomised trial conducted in
381	Tanzania evaluated three next generation LLINs, including LLINs treated with pyrethroid-
382	pyriproxyfen, pyrethroid-PBO, and pyrethroid-chlorfenapyr (a novel pyrrole insecticide), comparing
383	their effect on parasite prevalence measured by RDT in children aged 6 months to 14 years, as
384	compared to pyrethroid-only LLINs [19]. In this trial, parasite prevalence at 24 months post-
385	distribution in the pyrethroid-pyriproxyfen LLIN arm was no different than in the pyrethroid-PBO
386	control arm (37.5% vs 45.8%, adjusted OR 0.79 [95% Cl 0.54–1.17]). Similarly, a cluster-randomised
387	trial conducted in Benin studied pyrethroid-pyriproxyfen and pyrethroid-chlorfenapyr LLINs, as
388	compared to pyrethroid-only LLINs, evaluating their effect on malaria incidence in children aged 6
389	months to 10 years [30]. This study also found no difference between the pyrethroid-pyriproxyfen
390	and pyrethroid-only LLINs over 2 years following distribution (0.84 vs 1.03 malaria cases per child-
391	year, hazard ratio 0.86 [95% CI 0.65-1.14]). In both trials, only the pyrethroid-chlorfenapyr LLINs
392	were superior to the pyrethroid-only LLINs after two years [19, 30].

393

394	In March 2023, the WHO updated the guidelines on use of LLINs, supported by the recent results of
395	the trials in Tanzania and Benin, offering a conditional recommendation for the deployment of
396	pyrethroid-pyriproxyfen LLINs instead of pyrethroid-only LLINs in areas with pyrethroid resistance,
397	and highlighting concerns about the cost-effectiveness of the pyrethroid-pyriproxyfen LLINs [16]. In
398	addition, the WHO issued a conditional recommendation against the deployment of pyrethroid-
399	pyriproxyfen LLINs instead of pyrethroid-PBO LLINs, noting that the evidence favours pyrethroid-PBO
400	LLINs which were also deemed more cost-effective than pyriproxyfen LLINs. The LLINEUP2 trial adds
401	to the evidence of the effectiveness of pyrethroid-pyriproxyfen LLINs, but calls into question the
402	recent WHO recommendations, given that the pyrethroid-pyriproxyfen LLINs (Royal Guard, Disease
403	Control Technologies, USA) were less expensive than pyrethroid-PBO (PermaNet 3.0, Vestergaard
404	Sàrl, Switzerland) LLINs in our trial (\$2.30 USD for Royal Guard vs \$3.07 USD for PermaNet 3.0) [22],
405	with similar effectiveness. LLIN prices fluctuate, however, so this finding should not be generalised;
406	whichever net has a lower market price on a given day will be the most cost-effective.
407	
408	Malaria incidence was the primary outcome measure of the LLINEUP2 trial, which was a strength of
409	the study. Incidence of malaria, defined as the number of symptomatic cases of malaria occurring in
410	a population at risk over time, is considered the gold standard for assessing malaria burden.
411	However, cluster-randomised trials aiming to measure malaria incidence can be very expensive and
412	logistically challenging. In this trial, we leveraged a platform of enhanced health facility-based
413	malaria surveillance, which was built and supported by the Ugandan Malaria Surveillance Project
414	[31]. Although routinely collected health facility-based data are often limited by incomplete
415	reporting and lack of laboratory-confirmation, our enhanced health facility-based surveillance
416	system acts as an intervention, improving data quality, ensuring nearly all cases of malaria are

- 417 laboratory-confirmed, and improving case management. Moreover, by defining target areas around
- 418 MRCs, collecting data on village of residence of malaria, and enumerating the target area
- 419 populations to determine denominators, we estimated longitudinal measures of malaria incidence at

420	an unprecedented scale across Uganda, at relatively low cost. Embedding large-scale, cluster-
421	randomised trials into Uganda's national LLIN distribution campaigns has provided an innovative,
422	robust method to effectively evaluate next generation LLINs at scale, an exercise which would
423	otherwise be very costly. This design provides a new paradigm for trials evaluating the 'real-world'
424	effectiveness of malaria control interventions.
425	
426	This study had several limitations. First, due to resource limitations, entomologic surveillance and
427	assessments of LLIN bioefficacy and durability were not conducted. Second, we were not able to
428	survey the clusters prior to LLIN distribution, again due to lack of resources, and thus have no
429	baseline measures of LLIN coverage, parasite prevalence or anaemia. However, MRC surveillance
430	activities were ongoing for at least three months prior to LLIN distribution, providing baseline
431	measures of malaria incidence for all clusters. Third, although no difference in prevalence of
432	anaemia in children aged 2-4 years was observed between the pyrethroid-pyriproxyfen and
433	pyrethroid-PBO arms at the 12- and 24-month timepoints, anaemia prevalence dropped markedly in
434	both arms between the two surveys (pyrethroid-pyriproxyfen 34.0% to 19.0%; pyrethroid-PBO
435	36.2% to 19.7%). Reasons for this change are unclear but likely relate to variation around the
436	threshold cut-off for anaemia (haemoglobin < 11 g/dL) and the complex aetiology of anaemia.
437	Although malaria is a major cause of anaemia in endemic areas, other factors contribute including
438	nutritional status, helminths and other infections, and health system factors.
439	
440	Our results suggest that pyriproxyfen-pyrethroid LLINs could be an effective alternative to
441	pyrethroid-PBO LLINs in Uganda. Rotation of insecticides, including deployment of LLINs treated with
442	different insecticides, has been recommended as a strategy to manage insecticide resistance [32].
443	Supported by the recent trials in Tanzania and Benin, the WHO has also issued new guidelines on
444	LLINs treated with chlorfenapyr, offering a strong recommendation for the deployment of
445	pyrethroid-chlorfenapyr LLINs instead of pyrethroid-only LLINs, and a conditional recommendation

- 446 for deployment of pyrethroid-chlorfenapyr LLINs instead of pyrethroid-PBO LLINs in areas where
- 447 malaria vectors are resistant to pyrethroids. However, the evidence supporting these new
- 448 recommendations is limited and further research on the effectiveness, durability and lifespan of next
- generation LLINs is needed. To address the continuing challenge of insecticide resistance, we are
- 450 conducting another cluster-randomised trial (LLINEUP3) embedded with the 2023 universal coverage
- 451 campaign in collaboration with the Ugandan MOH. This study is comparing the effectiveness of
- 452 pyrethroid-chlorfenapyr LLINs versus pyrethroid-PBO LLINs in 24 clusters located in 20 districts in
- 453 Uganda.

454 **ACKNOWLEDGEMENTS**

- We would like to thank Emmanuel Arinaitwe, James Kapisi, Chris Ebong, Bridget Nzarubara, Faith 455 456 Kagoya, Emmanuel Bakashaba, Isiko Joseph, Paul Oketch, Benjamin Guma, Jolly Job Odongo, Daniel 457 Ochuli, Geoffrey Omia, Leuben Patrick Okello, Geoff Lavoy, Peter Mutungi, Nicholas Wendo, Yasin 458 Kisambira, Catherine Pitt and the administration of the Infectious Diseases Research Collaboration 459 for all their contributions. We would also like to acknowledge and thank the members of the Uganda 460 National Malaria Control Division and the Liverpool School of Tropical Medicine for logistical and 461 other support rendered as we carried out the data collection and analysis. We are grateful to the 462 district administration, health and political leadership teams for all their support and guidance 463 during community engagement in the 32 districts of the study area.
- 464

465 AUTHORS' CONTRIBUTIONS

- 466 SGS, GD, MRK, MJD, SG, CMS, JIN and JO conceived and designed the study. SGS, GD, MRK, JIN, SG,
- 467 JFN and CMS developed the procedures and drafted the protocol. SG, JFN, MJN, KS and IN collected
- the data, with oversight from SGS and MRK. IN and GD managed the data. GD, SG, KS, and SGS
- 469 analysed the data. JIN, AE, MJD and MRK advised on the analysis. SG, JFN, MJN, DG and SGS drafted
- the manuscript. All authors reviewed the manuscript, provided input and approved the final version
- 471 for publication.
- 472

473 DECLARATION OF INTERESTS

- 474 The authors declare that they have no competing interests.
- 475

476 FUNDING STATEMENT

- 477 This project was funded primarily by the US National Institutes for health, with additional funding
- 478 from the Bill and Melinda Gates Foundation. The content of the manuscript is solely the
- 479 responsibility of the authors.
- 480

481 DATA SHARING STATEMENT

- 482 De-identified participant data and a data dictionary defining each field in the set will be made
- 483 publicly available at the time of publication on the ClinEpiDB website (<u>https://clinepidb.org</u>). A link
- to the statistical analysis for the primary outcome has also been provided on the ClinEpiDB website
- 485 (https://clinepidb.org/ce/app/workspace/analyses/DS_624583e93e/5My0liA/visualizations/1fd2ff57
- 486 <u>-954e-4c58-bf39-ebb113cc5a70</u>).

489 **REFERENCES**

- 490 1) Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria
 491 control on Plasmodium falciparum in Africa between 2000 and 2015. Nature.
- 492 2015;526(7572):207-11. doi: 10.1038/nature15535. PubMed PMID: 26375008.
- 493 2) World Health Organization. World Malaria Report 2022. Geneva: World Health Organization,
- 494 2022 Contract No.: ISBN 978-92-4-006490-4.
- 495 3) Uganda National Malaria Control Division (NMCD), Uganda Bureau of Statistics (UBOS), ICF.
- 496 Uganda Malaria Indicator Survey 2018-19. Kampala, Uganda, and Rockville, Maryland, USA 2020.
- 4) Namuganga JF, Epstein A, Nankabirwa JI, Mpimbaza A, Kiggundu M, Sserwanga A, et al. The
 impact of stopping and starting indoor residual spraying on malaria burden in Uganda. Nat
 Commun. 2021;12(1):2635. Epub 2021/05/13. doi: 10.1038/s41467-021-22896-5. PubMed
 PMID: 33976132; PubMed Central PMCID: PMCPMC8113470.
- 5) Epstein A, Maiteki-Sebuguzi C, Namuganga JN, Nankabirwa JI, Gonahasa S, J. O, et al. Resurgence
 of malaria in Uganda despite sustained indoor residual spraying and repeated long lasting
 insecticidal net distributions. PLOS Global Public Health. 2022. doi:
 https://doi.org/10.1371/journal.pgph.0000676.
- 505 6) Pryce J, Richardson M, Lengeler C. Insecticide-treated nets for preventing malaria. Cochrane
 506 Database Syst Rev. 2018;11:CD000363. doi: 10.1002/14651858.CD000363.pub3. PubMed PMID:
 507 30398672.
- 508 7) World Health Organization. Achieving and maintaining universal coverage with long-lasting
 509 insecticidal nets for malaria control Geneva: World Health Organisation, Global Malaria
 510 Programme, 2017 Contract No.: WHO/HTM/GMP/2017.20.
- 8) Ranson H, Lissenden N. Insecticide Resistance in African Anopheles Mosquitoes: A Worsening
 Situation that Needs Urgent Action to Maintain Malaria Control. Trends Parasitol.
 2016;32(3):187-96. doi: 10.1016/j.pt.2015.11.010. PubMed PMID: 26826784.
- 9) Weetman D, Wilding CS, Neafsey DE, Muller P, Ochomo E, Isaacs AT, et al. Candidate-gene based
 GWAS identifies reproducible DNA markers for metabolic pyrethroid resistance from standing
- 516 genetic variation in East African Anopheles gambiae. Scientific reports. 2018;8(1):2920. doi:
- 517 10.1038/s41598-018-21265-5. PubMed PMID: 29440767; PubMed Central PMCID:
- 518 PMCPMC5811533.
- 10) Njoroge H, Van't Hof A, Oruni A, Pipini D, Nagi SC, Lynd A, et al. Identification of a rapidlyspreading triple mutant for high-level metabolic insecticide resistance in Anopheles gambiae
 provides a real-time molecular diagnostic for antimalarial intervention deployment. Molecular
 ecology. 2022;31(16):4307-18. Epub 2022/07/02. doi: 10.1111/mec.16591. PubMed PMID:
 35775282; PubMed Central PMCID: PMCPMC9424592.

11) Lynd A, Gonahasa S, Staedke SG, Oruni A, Maiteki-Sebuguzi C, Hancock PA, et al. LLIN Evaluation
 in Uganda Project (LLINEUP)-effects of a vector control trial on Plasmodium infection prevalence
 and genotypic markers of insecticide resistance in Anopheles vectors from 48 districts of

527 Uganda. Scientific reports. 2024;14(1):14488. Epub 20240624. doi: 10.1038/s41598-024-65050-

528 z. PubMed PMID: 38914669; PubMed Central PMCID: PMCPMC11196729.

- 529 12) Gleave K, Lissenden N, Chaplin M, Choi L, Ranson H. Piperonyl butoxide (PBO) combined with
 530 pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev.
 531 2021;5(5):Cd012776. Epub 2021/05/25. doi: 10.1002/14651858.CD012776.pub3. PubMed PMID:
 532 34027998; PubMed Central PMCID: PMCPMC8142305.
- 13) Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, et al. Effectiveness of
 a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray
 interventions, separately and together, against malaria transmitted by pyrethroid-resistant
 mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet.
 2018;391(10130):1577-88. doi: 10.1016/S0140-6736(18)30427-6. PubMed PMID: 29655496;
 PubMed Central PMCID: PMCPMC5910376.
- 539 14) Staedke SG, Gonahasa S, Dorsey G, Kamya MR, Maiteki-Sebuguzi C, Lynd A, et al. Effect of long540 lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda
 541 (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution
 542 campaign. Lancet. 2020;395(10232):1292-303. Epub 2020/04/20. doi: 10.1016/S0140543 6736(20)30214-2. PubMed PMID: 32305094; PubMed Central PMCID: PMCPMC7181182.
- 15) Maiteki-Sebuguzi C, Gonahasa S, Kamya MR, Katureebe A, Bagala I, Lynd A, et al. Effect of longlasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda
 (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution
 campaign. Lancet Infect Dis. 2023;23(2):247-58. Epub 2022/09/30. doi: 10.1016/S14733099(22)00469-8. PubMed PMID: 36174592.
- 549 16) World Health Organization. Guidelines for malaria. Geneva: World Health Organization, 2023 14
 550 March 2023. Report No.: Contract No.: WHO/UCN/GMP/2023.01.
- 17) Mechan F, Katureebe A, Tuhaise V, Mugote M, Oruni A, Onyige I, et al. LLIN evaluation in Uganda
 project (LLINEUP): The fabric integrity, chemical content and bioefficacy of long-lasting
 insecticidal nets treated with and without piperonyl butoxide across two years of operational
 use in Uganda. Curr Res Parasitol Vector Borne Dis. 2022;2:100092. Epub 2022/06/24. doi:
- 555 10.1016/j.crpvbd.2022.100092. PubMed PMID: 35734077; PubMed Central PMCID:
- 556 PMCPMC9207544.
- 18) Tiono AB, Ouedraogo A, Ouattara D, Bougouma EC, Coulibaly S, Diarra A, et al. Efficacy of Olyset
 Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against
 clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a clusterrandomised controlled trial. Lancet. 2018;392(10147):569-80. Epub 2018/08/15. doi:
- 561 10.1016/S0140-6736(18)31711-2. PubMed PMID: 30104047.

19) Mosha JF, Kulkarni MA, Lukole E, Matowo NS, Pitt C, Messenger LA, et al. Effectiveness and costeffectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal
nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: a four-arm, cluster-randomised
trial. Lancet. 2022;399(10331):1227-41. Epub 2022/03/28. doi: 10.1016/S0140-6736(21)02499-

566 5. PubMed PMID: 35339225; PubMed Central PMCID: PMCPMC8971961.

- 20) Nankabirwa JI, Rek J, Arinaitwe E, Namuganga JF, Nsobya SL, Asua V, et al. East Africa
 International Center of Excellence for Malaria Research: Summary of Key Research Findings. Am
 J Trop Med Hyg. 2022;107(4_Suppl):21-32. Epub 2022/10/14. doi: 10.4269/ajtmh.21-1285.
- 570PubMed PMID: 36228916; PubMed Central PMCID: PMCPMC9294681.
- 571 21) Okiring J, Gonahasa S, Nassali M, Namuganga JF, Bagala I, Maiteki-Sebuguzi C, et al. LLIN
 572 Evaluation in Uganda Project (LLINEUP2)-Factors associated with coverage and use of longlasting
 573 insecticidal nets following the 2020-21 national mass distribution campaign: a cross-sectional
 574 survey of 12 districts. Malar J. 2022;21(1):293. Epub 2022/10/20. doi: 10.1186/s12936-022575 04302-7. PubMed PMID: 36261818; PubMed Central PMCID: PMCPMC9580445.
- 576 22) The Global Fund to Fight AIDS TB and Malaria. Workbook: Price & Quality Reporting Transaction
 577 Summary (theglobalfund.org). 2023.
- 578 23) Mawejje HD, Wilding CS, Rippon EJ, Hughes A, Weetman D, Donnelly MJ. Insecticide resistance
 579 monitoring of field-collected Anopheles gambiae s.l. populations from Jinja, eastern Uganda,
 580 identifies high levels of pyrethroid resistance. Medical and veterinary entomology.
- 581
 2013;27(3):276-83. doi: 10.1111/j.1365-2915.2012.01055.x. PubMed PMID: 23046446; PubMed

 582
 Central PMCID: PMC3543752.
- 583 24) Mawejje HD, Weetman D, Epstein A, Lynd A, Opigo J, Maiteki-Sebuguzi C, et al. Characterizing
 584 pyrethroid resistance and mechanisms in Anopheles gambiae (s.s.) and Anopheles arabiensis
 585 from 11 districts in Uganda. Curr Res Parasitol Vector Borne Dis. 2023;3:100106. Epub
 586 2023/01/03. doi: 10.1016/j.crpvbd.2022.100106. PubMed PMID: 36590346; PubMed Central
 587 PMCID: PMCPMC9798136.
- 25) Riveron JM, Huijben S, Tchapga W, Tchouakui M, Wondji MJ, Tchoupo M, et al. Escalation of
 Pyrethroid Resistance in the Malaria Vector Anopheles funestus Induces a Loss of Efficacy of
 Piperonyl Butoxide-Based Insecticide-Treated Nets in Mozambique. J Infect Dis.
 2019;220(3):467-75. doi: 10.1093/infdis/jiz139. PubMed PMID: 30923819; PubMed Central
- 592 PMCID: PMCPMC6603977.
- 593 26) Gichuki PM, Kamau L, Njagi K, Karoki S, Muigai N, Matoke-Muhia D, et al. Bioefficacy and
 594 durability of Olyset([®]) Plus, a permethrin and piperonyl butoxide-treated insecticidal net in a 3595 year long trial in Kenya. Infectious diseases of poverty. 2021;10(1):135. Epub 2021/12/22. doi:
 596 10.1186/s40249-021-00916-2. PubMed PMID: 34930459; PubMed Central PMCID:
 597 PMCPMC8691082.
- 598 27) Lukole E, Cook J, Mosha JF, Messenger LA, Rowland M, Kleinschmidt I, et al. Protective efficacy
 599 of holed and aging PBO-pyrethroid synergist-treated nets on malaria infection prevalence in
 600 north-western Tanzania. PLOS Glob Public Health. 2022;2(10):e0000453. Epub 2023/03/25. doi:

601 10.1371/journal.pgph.0000453. PubMed PMID: 36962517; PubMed Central PMCID:
 602 PMCPMC10022078.

- 803 28) World Health Organization. World Health Organization: Report of the Fourth WHOPES Working
 604 Group Meeting In Review of IR3535; KBR3023; (RS)-Methoprene 20% EC, Pyriproxifen 05% GR;
 605 and Lamda-cyhalothrin 25% CS. Geneva, Switzerland: World Health Organization, 2001.
- 29) Lwetoijera DW, Harris C, Kiware SS, Killeen GF, Dongus S, Devine GJ, et al. Comprehensive
 sterilization of malaria vectors using pyriproxyfen: a step closer to malaria elimination. Am J Trop
 Med Hyg. 2014;90(5):852-5. Epub 2014/03/19. doi: 10.4269/ajtmh.13-0550. PubMed PMID:
 24639296; PubMed Central PMCID: PMCPMC4015577.
- 30) Accrombessi M, Cook J, Dangbenon E, Yovogan B, Akpovi H, Sovi A, et al. Efficacy of
 pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs
 compared with pyrethroid-only LLINs for malaria control in Benin: a cluster-randomised,
 superiority trial. Lancet. 2023;401(10375):435-46. Epub 2023/01/28. doi: 10.1016/S0140-
- 614 6736(22)02319-4. PubMed PMID: 36706778.
- 615 31) Epstein A, Namuganga JF, Kamya EV, Nankabirwa JI, Bhatt S, Rodriguez-Barraquer I, et al.
- Estimating malaria incidence from routine health facility-based surveillance data in Uganda.
- 617 Malar J. 2020;19(1):445. doi: 10.1186/s12936-020-03514-z. PubMed PMID: 33267886; PubMed
- 618 Central PMCID: PMCPMC7709253.
- World Health Organization. Global plan for insecticide resistance management in malaria
 vectors. Geneva, Switzerland: World Health Organization, 2012.

622 FIGURE LEGEND

624	Figure 1: Map of study area: The study included 64 clusters across 32 districts; 2 clusters per district,
625	one per study arm. A cluster was defined as a malaria reference centre and its target area.
626	
627	Figure 2: Trial profile. LLIN=long-lasting insecticidal net. BS=blood smear. Hb=haemoglobin.
628	
629	Figure 3: Malaria incidence per 1000 person-years. LLINs were distributed in waves over a period of
630	5 months. Malaria incidence measures cater for the staggered distribution of LLINs across the sites.
631	
632	
633	
634	

		12-month	surveys	24-month surveys		
Variable	Characteristic	pyrethroid-PBO LLINs	pyrethroid- pyriproxyfen LLINs	pyrethroid-PBO LLINs	pyrethroid- pyriproxyfen LLINs	
Number of households surveyed		1771	1747	1690	1682	
Measure of crowding, mean (SD)	2 3 persons / sleeping rooms	55.9% (15.4%)	57.4% (17.9%)	55.9% (14.6%)	53.1% (13.7%)	
	— Poorest	31.7% (22.3%)	35.6% (25.2%)	33.1% (21.9%)	33.6% (22.3%)	
Socioeconomic index in terciles, mean (SD)	— Poor	34.1% (13.7%)	33.4% (17.5%)	32.6% (14.0%)	35.4% (14.0%)	
	—Least poor	34.2% (23.3%)	31.0% (22.4%)	34.2% (25.1%)	31.0% (21.7%)	
	—Traditional	59.5% (32.7%)	62.2% (32.8%)	50.9% (30.7%)	56.5% (29.4%)	
Household construction, mean (SD)	— Modern	40.5% (32.7%)	37.8% (32.8%)	49.1% (30.7%)	43.5% (29.4%)	
Number of bed nets surveyed		3991	3790	3211	3095	
	—Most recent universal coverage campaign	92.4% (8.5%)	89.1% (14.2%)	87.1% (10.9%)	80.1% (18.4%)	
Where bed net was obtained, mean (SD)	— Prior universal coverage campaign	2.2% (4.8%)	2.0% (5.2%)	1.4% (2.5%)	3.2% (5.9%)	
	— Other	5.4% (5.5%)	8.9% (10.4%)	11.4% (9.3%)	16.8% (14.3%)	
Bed net obtained for free, mean (SD)		97.7% (2.7%)	96.9% (3.4%)	95.4% (5.1%)	94.1% (6.0%)	
Number of residents surveyed		8249	7940	8400	8306	
Female gender, mean (SD)		55.6% (3.9%)	54.8% (3.8%)	54.6% (3.2%)	54.2% (3.1%)	
	< 5 years	19.5% (3.8%)	18.6% (3.6%)	19.1% (3.8%)	18.6% (4.2%)	
Age categories, mean (SD)	5-15 years	33.9% (4.1%)	34.2% (5.0%)	33.6% (3.9%)	33.9% (4.5%)	
	16 years or older	46.5% (4.0%)	47.2% (3.7%)	47.4% (4.8%)	47.5% (4.6%)	

Table 1. Cluster-level characteristics of households, bed nets and household residents from cross-sectional surveys

^{*} Houses were dassified as 'modern' (synthetic walls and roofs, eaves closed or absent) or 'traditional' (all other construction)

Table 2. Malaria incidence in residence of all ages from MRC target areas

		Baseline *		24 months post-intervention				
Study arm	Episodes of malaria	Person years of observation	Malaria incidence per 1000 PY	Episodes of malaria	Person years of observation	Malaria incidence per 1000 PY	IRR (95% CI)**	p-value
pyrethroid-PBO LLINs	16,763	24,783	676	95,898	206,211	465	reference arm	
pyrethroid-pyriproxyfen LLINs	15,621	23,162	674	90,466	192,720	469	1.06 (0.91-1.22)	0.47

* 3 months prior to completion of LLIN distribution

** Adjusted for baseline malaria incidence; random effect at the level of the district

Table 3. Secondary outcomes assessed at 12- and 24-months post-intervention from cross-sectional surveys of MRC target areas

Indicator	Study arm	12-month survey			24-month survey			
multator		n/N (%)	OR (95% CI)	p-value	n/N (%)	OR (95% CI)	p-value	
	pyrethroid-PBO LLINs	1628/1771 (91.9%)	reference	_	1384/1690 (82.5%)	reference	_	
LLIN Ownership. In nouseholds	pyrethroid-pyriproxyfen LLINs	1571/1747 (89.9%)	0.81 (0.44-1.47)	0.48	1345/1682 (80.0%)	0.81 (0.45-1.47)	0.50	
	pyrethroid-PBO LLINs	1060/1771 (59.9%)	reference	-	695/1690 (41.1%)	reference	_	
Adequate LLIN coverage. In nouseholds	pyrethroid-pyriproxyfen LLINs	987/1747 (56.5%)	0.85 (0.58-1.25)	0.41	650/1682 (38.6%)	0.87 (0.56-1.36)	0.55	
	pyrethroid-PBO LLINs	6121/8249 (74.2%)	reference	—	5341/8400 (63.6%)	reference	—	
LLIN use+ in nousenoid residents	pyrethroid-pyriproxyfen LLINs	6045/7940 (76.1%)	0.98 (0.54-1.79)	0.96	5117/8306 (61.6%)	0.80 (0.41-1.58)	0.52	
	pyrethroid-PBO LLINs	521/2411 (21.6%)	reference	—	602/2311 (26.1 %)	reference	—	
Parasite prevalence in children 2-10 years	pyrethroid-pyriproxyfen LLINs	654/2482 (26.4%)	1.49 (0.88-2.51)	0.14	651/2208 (29.5%)	1.29 (0.81-2.05)	0.29	
	pyrethroid-PBO LLINs	385/1065 (36.2%)	reference	_	191/971 (19.7%)	reference	_	
Anaemia - prevalence in children 2-4 years	pyrethroid-pyriproxyfen LLINs	347/1022 (34.0%)	0.88 (0.57-1.34)	0.54	178/937 (19.0%)	0.95 (0.62-1.46)	0.81	

* LLIN ownership defined as household with at least 1 LLIN

[†] Adequate LLIN coverage defined as household with at least 1 LLIN for every 2 residents

‡ LLIN use defined as household resident who reported sleeping under a LLIN the prior night

** Anaemia defined as haemoglobin < 11 g/dL





